Bacterial resistance studies using in vitro dynamic models are highly dependent on the starting inoculum that might or might not contain spontaneously resistant mutants (RMs). To delineate concentration-resistance relationships with linezolid-exposed Staphylococcus aureus, a mixed inoculum containing both susceptible cells and RMs was used. An RM selected after the 9th passage of the parent strain (MIC, 2 g/ml) on antibiotic-containing media (RM9; MIC, 8 g/ml) was chosen for the pharmacodynamic studies, because the mutant prevention concentration (MPC) of linezolid against the parent strain in the presence of RM9 at 10 2 (but not at 10 4 ) CFU/ml did not differ from the MPC value determined in the absence of the RMs. Five-day treatments with twice-daily linezolid doses were simulated at concentrations either between the MIC and MPC or above the MPC. A specific mechanism of oxazolidinone action blocks functional initiation complexes in bacterial translation systems. Given the lack of analogues among available antimicrobials, a low probability of preexisting, naturally occurring resistance mechanisms has been hypothesized (1, 2). For example, resistance of Staphylococcus aureus rarely occurred through spontaneous mutations at frequencies of only 10 Ϫ9 to 10 Ϫ11 (3-5). However, the first report on the detection of a clinical isolate of S. aureus with a linezolid MIC of Ͼ32 g/ml was published as early as 2001 (6). Analysis of 23S rRNA encoding DNA sequences showed that linezolid-resistant S. aureus had a G-to-T mutation at position 2576 (Escherichia coli numbering). The same point mutations also were observed in S. aureus isolated in other clinical studies (7-14). Later, amino acid substitutions in ribosomal protein L3 (50S large-subunit ribosomal protein) were associated with oxazolidinone resistance (linezolid MIC, 8 g/ml) in a clinical S. aureus strain (15). Thus, clinical data indicate that resistance to linezolid mediated by mutations in ribosomal genes may emerge more readily than was initially predicted by routine in vitro studies performed early in the development of oxazolidinones, because they were not specifically designed to simulate antibiotic exposures that would allow the enrichment of resistant mutants.The resistance studies with linezolid cited above were not supported by concomitant pharmacokinetic studies to relate antibiotic concentrations to the selection of resistant mutants. To be sure, some in vitro model studies of the enrichment of resistant S. aureus simulated linezolid pharmacokinetics (16, 17).However, these attempts were unsuccessful because resistant mutants were not enriched, at least in simulations of oscillating antibiotic concentrations that mimic the usual linezolid dosing in humans. Linezolid-resistant staphylococci also were not enriched in other in vitro studies that were not designed to establish concentration-resistance relationships (18)(19)(20), probably because of the lack of spontaneous mutants in the starting inocula.To more clearly delineate concentration-resistance rel...
The bell-shaped pattern of AUC24/MIC and AUC24/MPC relationships with S. aureus resistance to linezolid is consistent with the MSW hypothesis. 'Antimutant' AUC24/MIC ratios were predicted based on the AUC24/MIC relationship with AUBCM.
Macrolide (MLR) and fluoroquinolone (FQR) resistance in Mycoplasma genitalium (MG) has recently become a major problem worldwide. The available data on the prevalence of MLR and FQR in MG in Russia are limited. In this study, we aimed to evaluate the prevalence and pattern of mutations in 213 MG-positive urogenital swabs from patients in Moscow between March 2021 and March 2022. MLR- and FQR-associated mutations were searched in 23S rRNA as well as in the parC and gyrA genes using Sanger sequencing. The prevalence of MLR was 55/213 (26%), with A2059G and A2058G substitutions being the two most common variants (36/55, 65%, and 19/55, 35%, respectively). FQR detection showed 17% (37/213); two major variants were D84N (20/37, 54%) and S80I (12/37, 32.4%) and three minor variants were S80N (3/37, 8.1%), D84G (1/37, 2.7%), and D84Y (1/37, 2.7%). Fifteen of the fifty-five MLR cases (27%) simultaneously harbored FQR. This study revealed the high frequency of MLR and FQR. We conclude that the improvement of patient examination algorithms and therapeutic approaches should be combined with the routine monitoring of antibiotic resistance based on the sensitivity profiles presented. Such a complex approach will be essential for restraining the development of treatment resistance in MG.
There is growing evidence of applicability of the hypothesis of the mutant selection window (MSW), i.e., the range between the MIC and the mutant prevention concentration (MPC), within which the enrichment of resistant mutants is most probable. However, it is not clear if MPC-based pharmacokinetic variables are preferable to the respective MIC-based variables as interstrain predictors of resistance. To examine the predictive power of the ratios of the area under the curve (AUC 24 ) to the MPC and to the MIC, the selection of ciprofloxacin-resistant mutants of three Klebsiella pneumoniae strains with different MPC/MIC ratios was studied. Each organism was exposed to twice-daily ciprofloxacin for 3 days at AUC 24 /MIC ratios that provide peak antibiotic concentrations close to the MIC, between the MIC and the MPC, and above the MPC. Resistant K. pneumoniae mutants were intensively enriched at an AUC 24 /MIC ratio of 60 to 360 h (AUC 24 /MPC ratio from 2.5 to 15 h) but not at the lower or higher AUC 24 /MIC and AUC 24 /MPC ratios, in accordance with the MSW hypothesis. AUC 24 /MPC and AUC 24 /MIC relationships with areas under the time courses of ciprofloxacin-resistant K. pneumoniae (AUBC M ) were bell shaped. These relationships predict highly variable "antimutant" AUC 24 /MPC ratios (20 to 290 h) compared to AUC 24 /MIC ratios (1,310 to 2,610 h). These findings suggest that the potential of the AUC 24 /MPC ratio as an interstrain predictor of K. pneumoniae resistance is lower than that of the AUC 24 /MIC ratio.A n increasing number of reports on the isolation of resistant pathogens (1, 2) combined with a weak antibiotic pipeline suggests that optimization of antibiotic therapy should be aimed at the suppression of resistance (3, 4). In this regard, dynamic models that mimic antimicrobial pharmacokinetics in vitro have been proven to be a useful tool in predicting the amplification of resistant mutants at clinically achievable antibiotic concentrations (5). Using these models, bell-shaped relationships have been established between the emergence of resistance to fluoroquinolones and the ratios of 24-hour area under the concentration-time curve (AUC 24 ) to the MIC (6-17). Such relationships have been reported with moxifloxacin, gatifloxacin, levofloxacin, ciprofloxacin, the investigational fluoroquinolone ABÒ492, pazufloxacin, tosufloxacin, and garenoxacin against Staphylococcus aureus (6-8, 14-16); moxifloxacin against Streptococcus pneumoniae (12, 13); garenoxacin against Klebsiella pneumoniae (15); ciprofloxacin and moxifloxacin against Pseudomonas aeruginosa (11, 12); and ciprofloxacin, marbofloxacin, and enrofloxacin against Escherichia coli (9,10,17). In some of these studies (6-15, 17, 18), changes in susceptibility of antibiotic-exposed bacteria and/or their enrichment with resistant mutants was observed at fluoroquinolone concentrations above the MIC but below the mutant prevention concentration (MPC), i.e., inside the mutant selection window (MSW) but not outside the MSW, in accordance with the MSW hypo...
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.